Stepwise sequential screening for fetal aneuploidy

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 3, 2007, Pages 312.e1-312.e5

  Benn, Peter A ^a   Campbell, Winston A ^a   Zelop, Carolyn M ^a   Ingardia, Charles ^a   Egan, James F X ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

amniocentesis; chorionic villus sampling; Down syndrome; prenatal screening; trisomy 18

Indexed keywords

ADULT; ANEUPLOIDY; ARTICLE; CHROMOSOME DELETION; CLINICAL PRACTICE; DOWN SYNDROME; FEMALE; FETUS KARYOTYPING; FIRST TRIMESTER PREGNANCY; GENETIC RISK; HUMAN; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; NUMERICAL CHROMOSOME ABERRATION; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; TRIPLOIDY; TRISOMY 18; TRISOMY 21;

EID: 34548443445     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.06.054     Document Type: Article

References (27)

1. Spencer K., Spencer C.E., Power M., Dawson C., and Nicolaides K.H. Screening for chromosome abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 110 (2003) 281-286
2. Wapner R., Thom E., Simpson J.L., et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 349 (2003) 1405-1413
3. Wald N.J., Rodeck C., Hackshaw A.K., Walters J., Chitty L., and Mackinson A.M. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10 (2003) 56-104 [Erratum J Med Screen 2006;13:51-2.]
4. Malone F.D., Canick J.A., Ball R.H., et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353 (2005) 2001-2011
5. Benn P.A., Fang M., Egan J.F.X., Horne D., and Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol 101 (2003) 451-454
6. Wald N.J., Huttley W.J., and Hackshaw A.K. Antenatal screening for Down syndrome with the quadruple test. Lancet 361 (2003) 835-836
7. Cuckle H., Benn P., and Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Neonatol 29 (2005) 252-257
8. Wald N., Watt H.C., and Hackshaw A.K. Integrated screening for Down syndrome based on tests performed during the first and second trimesters. N Engl J Med 341 (1999) 461-467
9. Wright D., Bradbury I., Benn P., Cuckle H., and Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 24 (2004) 762-766
10. Benn P.A., Wright D., and Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 25 (2005) 645-652
11. Platt L.D., Greene N., Johnson A., et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 104 (2004) 661-666
12. Malone F.D. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 105 (2005) 438-439
13. Benn P.A., and Donnenfeld A.E. Sequential Down syndrome screening; the importance of first and second trimester test correlations when calculating risk. J Genet Counsel 14 (2005) 409-413
14. American College of Obstetricians and Obstetricians. Screening for fetal chromosome abnormalities: ACOG practice bulletin. Obstet Gynecol 109 (2007) 217-227
15. Summers A.M., Huang T., Meier C., and Farrell S.A. Contingent screening for Down syndrome. Prenat Diagn 25 (2005) 963
16. Canick J.A., Lambert-Messerlian G., Palomaki G.E., et al. Comparison of serum markers in first-trimester Down syndrome screening. Obstet Gynecol 108 (2006) 1192-1199
17. Palomaki G.E., Haddow J.E., Knight G.J., et al. Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Prenat Diagn 15 (1995) 713-723
18. Tul N., Spencer K., Noble P., Chan C., and Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free â-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19 (1999) 1035-1042
19. Palomaki G.E., Neveux L.M., Knight G.J., and Haddow J.E. Maternal-serum integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn 23 (2003) 243-247
20. Benn P.A. Recurrence risks. Down's Screening News 12 (2005) 4-5
21. Benn P.A., Fang M., and Egan J.F.X. Trends in the use of second trimester maternal serum screening from 1991 to 2003. Genet Med 7 (2005) 328-331
22. Souka A.P., von Kaisenberg C.S., Hyett J.A., Sonek J.D., and Nicolaides K.H. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192 (2005) 1005-1021
23. Cuckle H.S., and Arbuzova S. Multimarker maternal serum screening for chromosome abnormalities. In: Milunsky A. (Ed). Genetic disorders and the fetus. 5th ed. (2004), Johns Hopkins University Press, Baltimore (MD) 795-835
24. Benn P.A., and Fang M. Maternal serum screening for Down syndrome, trisomy 18, and other fetal chromosome abnormalities. J Clin Ligand Soc 26 (2003) 129-136
25. Milunsky A., and Canick J.A. Maternal serum screening for neural tube and other defects. In: Milunsky A. (Ed). Genetic disorders and the fetus. 5th ed. (2004), Johns Hopkins University Press, Baltimore (MD) 719-794
26. Huttly W.J., Morris J.K., Bestwick J.P., Wald N.J., Murphy K., and Pandya P.P. Three stage contingent screening for Down syndrome [letter]. Prenat Diagn 26 (2006) 1183
27. Chen J., Heffley D., Beazoglou T., and Benn P.A. Utilization of amniocentesis by women screen-positive for Down syndrome by the second trimester triple test. Community Genet 3 (2000) 24-30